aTyr Pharma, Inc. filings document a clinical-stage biotechnology issuer focused on tRNA synthetase-derived medicines and the efzofitimod program for interstitial lung disease. Form 8-K reports furnish quarterly and annual results, corporate updates, and clinical-study disclosures, including EFZO-FIT results in pulmonary sarcoidosis.
Proxy materials describe board elections, stockholder meeting proposals, executive compensation, equity awards, and governance practices. The filing record also reflects capital-structure and stock-based compensation disclosures relevant to a development-stage biotechnology company funding research, clinical trials, and manufacturing activities for its lead program.
FMR LLC and Abigail P. Johnson report passive ownership of ATYR PHARMA INC common stock on an amended Schedule 13G. FMR LLC beneficially owns 2,471,418 shares, representing 2.5% of the common stock outstanding. FMR LLC has sole voting power over 2,464,141 of these shares and sole dispositive power over the full 2,471,418 shares, with no shared voting or dispositive power reported.
Abigail P. Johnson is reported as having sole dispositive power over the same 2,471,418 shares, but no sole or shared voting power, reflecting her control position over FMR-related entities. The filing confirms ownership of 5 percent or less of the class and notes that one or more other persons may receive dividends or sale proceeds, although no other person’s interest exceeds five percent of ATYR PHARMA INC’s common stock.
aTyr Pharma, Inc. entered into a Termination Agreement with Kyorin Pharmaceutical Co., Ltd. effective July 30, 2026, formally ending their 2020 collaboration and license arrangement for efzofitimod in Japan. All licenses Kyorin held under the prior agreement, including exclusive rights to develop and commercialize efzofitimod for interstitial lung disease in Japan, ceased on the termination date, and those exclusive territorial rights reverted to aTyr. As a result, aTyr now holds the right to develop and commercialize efzofitimod globally.
Under the agreement, Kyorin grants aTyr worldwide, irrevocable, perpetual, royalty‑free licenses to Kyorin Background Technology (non‑exclusive) and to New Kyorin IP and Kyorin’s interest in New Joint IP (exclusive) related to the Reversion Products. Kyorin will transfer extensive clinical, regulatory and manufacturing data, including Handover Documents and Essential Documents, and will assign to aTyr the Japanese orphan drug designation for efzofitimod, while continuing certain sponsor responsibilities and archival obligations during a transition period of up to twelve (12) months. The parties mutually release claims under the prior collaboration arising before the termination date and confirm there are no outstanding development cost payments owed by Kyorin to aTyr.
BlackRock, Inc. filed an amended Schedule 13G reporting its passive ownership in aTYR PHARMA INC common stock. BlackRock reports beneficial ownership of 1,725,072 shares of common stock, representing 1.8% of the class.
BlackRock has sole voting power and sole dispositive power over all 1,725,072 shares, with no shared voting or dispositive power. Various underlying clients or funds have rights to dividends or sale proceeds, but no single person’s interest exceeds five percent of aTYR PHARMA’s outstanding common shares.
Federated Hermes, Inc. filed an amendment on Schedule 13G/A reporting beneficial ownership of 8,509,678 shares of common stock of aTYR PHARMA INC, equal to 8.68% of the class as shown on the cover pages dated 06/30/2026. The filing includes a Rule 13d-4 disclaimer that Federated Hermes, the Voting Shares Irrevocable Trust and related individuals expressly disclaim beneficial ownership of securities held by the managed funds.
aTyr Pharma, Inc. received an additional 180-day period from Nasdaq to regain compliance with the exchange’s minimum bid price requirement for continued listing. The company now has until November 30, 2026 for its stock to close at or above $1.00 for at least 10 consecutive business days.
The extension was granted because aTyr meets other Nasdaq Capital Market listing standards, including market value of publicly held shares, and has stated its intention to cure the deficiency, potentially through a reverse stock split. The company’s shares remain listed while it monitors its stock price and evaluates options.
ATYR PHARMA INC reports an Amendment No. 14 to a Schedule 13G/A disclosing that FMR LLC beneficially owns 5,935,900 shares of Common Stock, representing 6.1% of the class. The filing lists voting and dispositive powers attributed to FMR LLC and Abigail P. Johnson and references an exhibit concerning a 13d-1(k) agreement.
aTyr Pharma furnished an investor presentation outlining updated clinical data and plans for its lead biologic immunomodulator efzofitimod in pulmonary sarcoidosis and other interstitial lung diseases. The Phase 3 EFZO-FIT trial, the largest interventional pulmonary sarcoidosis study to date, did not meet its primary endpoint of reducing oral corticosteroid dose versus placebo, but showed higher steroid-free rates and improvements in multiple quality-of-life measures at the 5 mg/kg dose while maintaining lung function and a generally favorable safety profile.
The company describes FDA feedback from a Type C meeting supporting forced vital capacity (FVC) and KSQ-L as clinically meaningful endpoints, with FVC selected as the primary endpoint for a new Phase 3 trial (C-006) in patients with restrictive pulmonary sarcoidosis. Efzofitimod is also being tested in the Phase 2 EFZO-CONNECT study for systemic sclerosis-associated ILD and supported by a broader tRNA synthetase–based pipeline, including preclinical fibrosis candidate ATYR0101 and a proprietary tRNA synthetase library targeting inflammatory and fibrotic diseases.
aTyr Pharma director Paul Schimmel reported an open-market purchase of 100,000 shares of aTyr Pharma common stock on May 27, 2026 at a weighted average price of $0.4963 per share.
According to the filing, these shares were bought in multiple trades between $0.4907 and $0.50 per share and are held indirectly through entities associated with Schimmel as noted in the footnotes.
aTyr Pharma, Inc. reported first quarter 2026 results and outlined next steps for its lead drug efzofitimod in interstitial lung disease. The company plans to submit an IND in June 2026 for a global Phase 3 pulmonary sarcoidosis study and is on track to complete enrollment in its Phase 2 EFZO-CONNECT SSc-ILD trial in the first half of 2026.
aTyr ended the quarter with $68.3 million in cash, cash equivalents, restricted cash and investments. Net loss attributable to aTyr was $10.8 million, compared with $14.9 million a year earlier, with net loss per share of $0.11 versus $0.17 in 2025. Research and development expenses were $7.3 million and general and administrative expenses were $4.1 million for the quarter.